Shaping the future management of hepatocellular carcinoma

Ghassan Abou-Alfa, Massimo Colombo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Several advances in recent years have led to improved surveillance, diagnostic, and treatment options for hepatocellular carcinoma (HCC). Despite these advances, care for this malignancy remains suboptimal, in part because of poor adherence to established guidelines. When diagnosed at an early stage, outcomes for HCC are positive; however, use of appropriate screening techniques and surveillance of at risk patients is still not widely employed. Although a multidisciplinary care team is considered an essential part of successful HCC treatment, fewer than half of the patients with HCC in the United States receive multidisciplinary care. The current suboptimal utilization of potentially curative treatments, including those recommended by treatment guidelines, can be linked to the absence of multidisciplinary care. Additionally, the lack of prognostic and predictive biomarkers for HCC remains challenging, particularly as therapeutic approaches in advanced disease evolve to the use of molecularly targeted agents. Much research is currently focused on the identification of biomarkers for HCC, but improvements in adherence to guidelines for surveillance and appropriate use of available therapies is necessary before care for patients with HCC will improve.

Original languageEnglish
JournalSeminars in Liver Disease
Volume33
Issue numberSUPPL.1
DOIs
Publication statusPublished - 2013

Fingerprint

Hepatocellular Carcinoma
Therapeutics
Biomarkers
Guidelines
Guideline Adherence
Patient Care
Research
Neoplasms

Keywords

  • HCC biomarkers
  • HCC surveillance
  • hepatocellular carcinoma
  • liver cancer
  • multidisciplinary care

ASJC Scopus subject areas

  • Hepatology

Cite this

Shaping the future management of hepatocellular carcinoma. / Abou-Alfa, Ghassan; Colombo, Massimo.

In: Seminars in Liver Disease, Vol. 33, No. SUPPL.1, 2013.

Research output: Contribution to journalArticle

@article{70946af5cadd41a5a381a207220285b8,
title = "Shaping the future management of hepatocellular carcinoma",
abstract = "Several advances in recent years have led to improved surveillance, diagnostic, and treatment options for hepatocellular carcinoma (HCC). Despite these advances, care for this malignancy remains suboptimal, in part because of poor adherence to established guidelines. When diagnosed at an early stage, outcomes for HCC are positive; however, use of appropriate screening techniques and surveillance of at risk patients is still not widely employed. Although a multidisciplinary care team is considered an essential part of successful HCC treatment, fewer than half of the patients with HCC in the United States receive multidisciplinary care. The current suboptimal utilization of potentially curative treatments, including those recommended by treatment guidelines, can be linked to the absence of multidisciplinary care. Additionally, the lack of prognostic and predictive biomarkers for HCC remains challenging, particularly as therapeutic approaches in advanced disease evolve to the use of molecularly targeted agents. Much research is currently focused on the identification of biomarkers for HCC, but improvements in adherence to guidelines for surveillance and appropriate use of available therapies is necessary before care for patients with HCC will improve.",
keywords = "HCC biomarkers, HCC surveillance, hepatocellular carcinoma, liver cancer, multidisciplinary care",
author = "Ghassan Abou-Alfa and Massimo Colombo",
year = "2013",
doi = "10.1055/s-0033-1333633",
language = "English",
volume = "33",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers, Inc.",
number = "SUPPL.1",

}

TY - JOUR

T1 - Shaping the future management of hepatocellular carcinoma

AU - Abou-Alfa, Ghassan

AU - Colombo, Massimo

PY - 2013

Y1 - 2013

N2 - Several advances in recent years have led to improved surveillance, diagnostic, and treatment options for hepatocellular carcinoma (HCC). Despite these advances, care for this malignancy remains suboptimal, in part because of poor adherence to established guidelines. When diagnosed at an early stage, outcomes for HCC are positive; however, use of appropriate screening techniques and surveillance of at risk patients is still not widely employed. Although a multidisciplinary care team is considered an essential part of successful HCC treatment, fewer than half of the patients with HCC in the United States receive multidisciplinary care. The current suboptimal utilization of potentially curative treatments, including those recommended by treatment guidelines, can be linked to the absence of multidisciplinary care. Additionally, the lack of prognostic and predictive biomarkers for HCC remains challenging, particularly as therapeutic approaches in advanced disease evolve to the use of molecularly targeted agents. Much research is currently focused on the identification of biomarkers for HCC, but improvements in adherence to guidelines for surveillance and appropriate use of available therapies is necessary before care for patients with HCC will improve.

AB - Several advances in recent years have led to improved surveillance, diagnostic, and treatment options for hepatocellular carcinoma (HCC). Despite these advances, care for this malignancy remains suboptimal, in part because of poor adherence to established guidelines. When diagnosed at an early stage, outcomes for HCC are positive; however, use of appropriate screening techniques and surveillance of at risk patients is still not widely employed. Although a multidisciplinary care team is considered an essential part of successful HCC treatment, fewer than half of the patients with HCC in the United States receive multidisciplinary care. The current suboptimal utilization of potentially curative treatments, including those recommended by treatment guidelines, can be linked to the absence of multidisciplinary care. Additionally, the lack of prognostic and predictive biomarkers for HCC remains challenging, particularly as therapeutic approaches in advanced disease evolve to the use of molecularly targeted agents. Much research is currently focused on the identification of biomarkers for HCC, but improvements in adherence to guidelines for surveillance and appropriate use of available therapies is necessary before care for patients with HCC will improve.

KW - HCC biomarkers

KW - HCC surveillance

KW - hepatocellular carcinoma

KW - liver cancer

KW - multidisciplinary care

UR - http://www.scopus.com/inward/record.url?scp=84874397662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874397662&partnerID=8YFLogxK

U2 - 10.1055/s-0033-1333633

DO - 10.1055/s-0033-1333633

M3 - Article

C2 - 23457036

AN - SCOPUS:84874397662

VL - 33

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - SUPPL.1

ER -